Multi-species toxicology approaches for oncology drugs: The US perspective

European Journal of Cancer

Volumn 40, Issue 6, 2004, Pages 907-913

  Tomaszewski, Joseph E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Animals; Antineoplastic agents; Drug evaluation; Models; Pharmacology; Preclinical; Toxicology

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYTOTOXIC AGENT; OLIGONUCLEOTIDE;

ANOREXIA; BIOTECHNOLOGY; CANCER RESEARCH; CLINICAL RESEARCH; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; EXPERIMENTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY; VOMITING;

EID: 1942454387     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.024     Document Type: Article

References (40)

1. Double J. Toxicity testing in the development of anticancer drugs. Lancet Oncol. 3:2002;438-439.
2. Druker B.J., Talpaz M., Resta D.J., Peng B.et al. Efficacy and safety of a specific inhibitor of BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
3. Druker B.J., Sawyers C.L., Kantarjian H.et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia Chromosome. N. Engl. J. Med. 344:2001;1038-1042.
4. Gleevec™ prescribing information. Physicians' Desk Reference, Medical Economics Company, Montvale, NJ, 2002, 2357-2360.
5. Adjei A.A., Erlichman C., Davis J.N.et al. A phase I trial of the farnesyl transferase inhibitor SCH66336. evidence for biological and clinical activity Cancer Res. 60:2000;1871-1877.
6. Zujewski J., Horak I.D., Bol C.J.et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18:2000;927-941.
7. ICH Guidance to Industry: M3, Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (July 1997).
8. DeGeorge J.J., Ahn C., Andrews P.A.et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol. 41:1998;173-185.
9. Burtles S.S., Newell D.R., Henrar R.E., Connors T.A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. Eur. J. Cancer. 31:1995;408-410.
10. Grieshaber C.K., Marsoni S. Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep. 70:1986;65-72.
11. Olson H., Betton G., Robinson D.et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32:2000;56-67.
12. Parkinson C., Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Hum. Exp. Toxicol. 12:1993;99-109.
13. Broadhead C.L., Benton G., Combes R.et al. Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Hum. Exp. Toxicol. 19:2000;440-447.
14. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 2:1997;436-444.
15. Grieshaber C.K. Agent-directed preclinical toxicology for new antineoplastic drugs. Valeriote F.A., Corbett T.H., Baker L.H.et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. 1992;247-260 Kluwer Academic Publishers, Boston.
16. Tomaszewski J.E., Smith A.C. Chapter 23, Safety testing of antitumor agents. Williams P.D., Hottendorf G.H. Comprehensive Toxicology, Toxicity Testing and Evaluation, Vol. 2. 1997;299-309 Elsevier Science Ltd, Oxford, England.
17. Tomaszewski J.E., Smith A.C., Covey J.M., Donohue S.J., Rhie J.K., Schweikart K.M. Chapter 17, Relevance of preclinical pharmacology and toxicology to phase I trial extrapolation techniques. Relevance of animal toxicology. Baguley B.C. Anti-Cancer Drug Design. 2001;301-328 Academic Press, San Diego, CA.
18. Joint Steering Committee of the EORTC and CRC General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur. J. Cancer. 26:1990;411-414.
19. Newell D.R., Burtles S.S., Fox B.W., Jodrell D.I., Connors T.A. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br. J. Cancer. 81:1999;760-768.
20. Dent S.F., Eisenhauer E.A. Phase I trial design. are new methodologies being put into practice? Ann. Oncol. 7:1996;561-566.
21. Verweij J. Starting dose levels for phase I studies. Proceedings of the 9TH NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1996, 13 (Abstract).
22. Arbuck S.G. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann. Oncol. 7:1996;567-573.
23. Smith AC, Tomaszewski JE. Correlation of human toxicity and MTDs with preclinical animal data, presented at the preclinical pharmacology and toxicology workshop at the EORTC/NCI/AACR Meeting, Frankfurt Germany, 2002.
24. Clark D.L., Andrews P.A., Smith D.D., DeGeorge J.J., Justice R.L., Beitz J.G. Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin. Cancer Res. 5:1999;1161-1167.
25. Adams J., Palombella V.J., Sausville E.A.et al. Proteasome inhibitors. a novel class of potent and effective antitumor agents Cancer Res. 59:1999;2615-2622.
26. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 7:2002;9-16.
27. Millar A.W., Brown P.D., Moore J.et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45:1998;21-26.
28. Pilaro A.M., Serabian M.A. Preclinical development strategies for novel gene therapy products. Toxicol. Pathol. 27:1999;4-7.
29. Pilaro AM. Preclinical animal models in gene therapy research. Biological Response Modifiers Advisory Committee Meeting, November 17, 2000.
30. Black L.E., DeGeorge J.J., Cavagnaro J.A., Jordan A., Ahn C.H. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res. Dev. 3:1993;399-404.
31. Black L.E., Farrelly J.G., Cavagnaro J.A.et al. Regulatory considerations for oligonucleotide drugs. updated recommendations for pharmacology and toxicology studies Antisense Res. Dev. 4:1994;299-301.
32. ICH Guidance to Industry: S7A, Safety Pharmacology Studies for Human Pharmaceuticals (July 2001).
33. ICH Guidance to Industry: S7B, Guideline on Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (February 2002).
34. Schweikart K.M., Parchment R., Osborn B.et al. In vitro/in vivo bone marrow toxicity. comparison of clinical and preclinical data for selected anticancer drugs Proc. Amer. Assoc. Cancer Res. 36:1995;367. (abstr 2185).
35. Tomaszewski JE, Schweikart KM, Parchment RE. Correlation of clinical and preclinical bone marrow toxicity data for selected anticancer drugs. First International Symposium on Hematotoxicology in New Drug Development, Lugano, Switzerland, 1997.
36. Tomaszewski JE, Schweikart KM, Parchment RE. Correlation of clinical and preclinical bone marrow toxicity data for selected anticancer drugs. In Vitro Human Tissue Models in Risk Assessment Workshop of the Society of Toxicology, Ellicot Ciity, MD, 1999.
37. Parchment R., Tomaszewski J., Schweikart K., LoRusso P. Success in predicting human maximum tolerated dose from in vitro data and mouse MTD. Proc. Amer. Assoc. Cancer Res. 43:2002;208-209. (abstr 1046).
38. Pessina A., Albella B., Bayo M.et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia. an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics Toxicol. Sci. 75:2003;355-367.
39. Hollingshead M.G., Alley M.C., Camalier R.F.et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57:1995;131-141.
40. Hollingshead M., Roberson J., Decker W.et al. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice. Antiviral. Res. 28:1995;265-279.